Zum Hauptinhalt springen

Perkutane Koronarintervention

Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:


  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Langfassung, 5. Aufl. 2019. www.leitlinien.de 
  • Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Neue Thrombozyten-Aggregationshemmer. Einsatz in der Hausarztpraxis. AWMF-Leitlinie 053-041. S2e, Stand 2019. www.awmf.org 
  • European Society of Cardiology. Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Stand 2020. www.escardio.org 
  • European Society of Cardiology. Guidelines for the diagnosis and management of chronic coronary syndromes. Stand 2019. www.escardio.org 
  • European Society of Cardiology. Focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Stand 2017. www.escardio.org 
  • European Society of Cardiology. Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Stand 2017. www.escardio.org 
  • European Society of Cardiology. Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Stand 2020. www.escardio.org 
  • European Society of Cardiology and European Association for Cardio-Thoracic Surgery. Guidelines on myocardial revascularization. Stand 2018. www.escardio.org 
  • European Society of Cardiology. Guidelines on the management of stable coronary artery disease. Stand 2013. www.escardio.org 
  • European Society of Cardiology/European Society of Anaesthesiology. Guidelines on non-cardiac surgery: cardiovascular assessment and management. Stand 2014. www.escardio.org 
  1. Diodato M, Chedrawy E. Coronary Artery Bypass Graft Surgery: The Past, Present, and Future of Myocardial Revascularisation. Surgery Research and Practice 2014; 2014: 1-6. doi:10.1155/2014/726158 DOI  
  2. Gruentzig A. Results from coronary angioplasty and implications for the future. Am Heart J 1982; 103: 779-783. doi:10.1016/0002-8703(82)90486-0 DOI  
  3. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. New Engl J Med 1987; 316: 701-716. pmid:2950322 PubMed  
  4. Serruys P, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.. New Engl J Med 1994; 331: 489-495. doi:10.1056/NEJM199408253310801 DOI  
  5. Dehmer GJ, Smith KJ. Drug-eluting coronary artery stents. Am Fam Physician 2009; 80: 1245-51. pubmed.ncbi.nlm.nih.gov  
  6. Nikam N, Steinberg T, Steinberg D. Advances in stent technologies and their effect on clinical ef cacy and safety. Med Devices (Auckl) 2014; 2014: 165-178. doi:10.2147/MDER.S31869 DOI  
  7. Parisi A, Folland E, Hartigan P, et al. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992; 326: 10-16. doi:10.1056/NEJM199201023260102 DOI  
  8. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol 2005; 46: 2004-9. PubMed  
  9. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988; 318: 1734-7. New England Journal of Medicine  
  10. Serruys P, Luijten H, Beatt K, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371. doi:10.1161/01.CIR.77.2.361 DOI  
  11. Gershlick A, de Bono D. Restenosis after angioplasty. Br Heart J 1990; 64: 351-353. www.ncbi.nlm.nih.gov  
  12. Fischman DL, Leon MB, Baim DS, et al., Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501. New England Journal of Medicine  
  13. Mintz GS, Hoffmann R, Mehran R, et al. In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol 1998; 81: 7E–13E. www.ajconline.org  
  14. Ho M, Chen C, Wang C, et al. The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types. Metals 2016; 6: 168. doi:10.3390/met6070168 DOI  
  15. Dietz R, Silber S, Baumgart D, et al. Positionspapier zur intrakoronaren Brachytherapie. Z Kardiol 2001; 90: 875–880. leitlinien.dgk.org  
  16. Moses JW, Leon MB, Popma JJ, et al., for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23. New England Journal of Medicine  
  17. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92: 641-9. PubMed  
  18. Byrne R, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J 2015; 36: 3320–3331. doi:10.1093/eurheartj/ehv511 DOI  
  19. Bønaa K, Mannsverk J, Wiseth R, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. New Engl J Med 2016; 375: 1242-1252. doi:10.1056/NEJMoa1607991 DOI  
  20. Sarno G, Bo Lagerqvist1 B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33: 606–613. doi:10.1093/eurheartj/ehr479 DOI  
  21. Iqbal J, Gunn J, Serruys P. Coronary stents: historical development, current status and future directions. Br Med Bull 2013; 106: 193–211. doi:10.1093/bmb/ldt009 DOI  
  22. Kristensen S, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 2014; 35: 2383-2431. doi:10.1093/eurheartj/ehu282 DOI  
  23. Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–254. doi:10.1093/eurheartj/ehx419 DOI  
  24. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014; 35: 765-776. doi:10.1093/eurheartj/eht542 DOI  
  25. Ali Z, Serruys P, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet 2017; 390: 760-772. doi:10.1016/S0140-6736(17)31470-8 DOI  
  26. Scheller B, Hennen B, Severin-Kneib S, et al. Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. Am J Med 2001; 110: 1-6. pmid:11152857 PubMed  
  27. Nordmann A, Hengstler P, Harr T, et al. Clinical Outcomes of Primary Stenting versus Balloon Angioplasty in Patients with Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. Am J Med 2004; 116: 253-262. doi:10.1016/j.amjmed.2003.08.035 DOI  
  28. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713. doi:10.1093/eurheartj/ehm402 pubmed.ncbi.nlm.nih.gov  
  29. Räber L, Kelbak H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-787. doi:10.1001/jama.2012.10065 DOI  
  30. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled tria. Lancet 2012; 380: 1482–1490. doi:10.1016/S0140-6736(12)61223-9 DOI  
  31. Sabate M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet 2016; 357: 357-366. doi:10.1016/S0140-6736(15)00548-6 DOI  
  32. Collet J, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020; 00: 1-79. www.escardio.org  
  33. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. leitlinien.dgk.org  
  34. Boden W, O'Rourke R, Teo K, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New Engl J Med 2007; 356: 2007. doi:10.1056/NEJMoa070829 DOI  
  35. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New Engl J Med 2009; 360: 2503-2515. doi:10.1056/NEJMoa0805796 DOI  
  36. Nishigaki K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. J Am Coll Cardiol Intv 2008; 1: 469-479. doi:10.1016/j.jcin.2008.08.002 DOI  
  37. Stergiopoulos K, Brown D. Initial Coronary Stent Implantation With Medical Therapy vs Medical Therapy Alone for Stable Coronary Artery Disease. Arch Intern Med 2012; 172: 312-319. doi:10.1001/archinternmed.2011.1484 DOI  
  38. Park S, Ahn J, Kim Y, et al. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. New Engl J Med 2015; 372: 1204-1212. doi:10.1056/NEJMoa1415447 DOI  
  39. Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. New Engl J Med 2015; 372: 1213-1222. www.ncbi.nlm.nih.gov  
  40. Mohr F, Morice M, Kappetein K, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629–638. doi:10.1016/S0140-6736(13)60141-5 DOI  
  41. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 5. Aufl. 2019. www.leitlinien.de  
  42. Jaffe R, Strauss B. Late and Very Late Thrombosis of Drug-Eluting Stents. J Am Coll Cardiol 2007; 50: 119-127. doi:10.1016/j.jacc.2007.04.031 DOI  
  43. Sudhir K, Hermiller J, Ferguson J, et al. Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy. ISRN Cardiology 2013; 2013: 1-8. doi:10.1155/2013/748736 DOI  
  44. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30. pubmed.ncbi.nlm.nih.gov  
  45. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-9. pubmed.ncbi.nlm.nih.gov  
  46. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-8. PubMed  
  47. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111. doi:10.1016/j.jacc.2005.11.092 DOI  
  48. Pfisterer M, Brunner-La Rocca H, Buser P, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2007; 48: 2584-2591. doi:10.1016/j.jacc.2006.10.026 DOI  
  49. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA 2008; 299: 2868-76. PubMed  
  50. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-9. New England Journal of Medicine  
  51. Stefanini G, Kalesan B, Serruys P, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940–1948. doi:10.1016/S0140-6736(11)61672-3 DOI  
  52. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34: 2949-3003. www.ncbi.nlm.nih.gov  
  53. European Society of Cardiology and European Association for Cardio-Thoracic Surgery. Guidelines on myocardial revascularization, Stand 2018. www.escardio.org  
  54. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407-477. doi:10.1093/eurheartj/ehz425 www.escardio.org  
  55. Eikelboom J, Connolly S, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330. doi:10.1056/NEJMoa1709118 DOI  
  56. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Neue Thrombozyten-Aggregationshemmer - Einsatz in der Hausarztpraxis. DEGAM-Leitlinie Nr. 16, AWMF-Leitlinie 053-041. Stand 2019. www.awmf.org  
  57. Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes. N Engl J Med 2019; 381: 1524-1534. doi:10.1056/NEJMoa1908973 DOI  
  58. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 00: 1-126. www.escardio.org  
  59. Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis? Int J Clin Pharmacol Ther 2009;47(1):1-10. pubmed.ncbi.nlm.nih.gov  
  60. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119: 1634-42. pubmed.ncbi.nlm.nih.gov  
  • Michael Handke, Prof. Dr. med., Facharzt für Innere Medizin, Kardiologie und Intensivmedizin, Freiburg i. Br.